Skip to main content
Premium Trial:

Request an Annual Quote

Intradigm, Europroteome Pen siRNA Cancer Collaboration

NEW YORK, July 17 - Intradigm will apply its small interfering RNA delivery technology to one of Europroteome's cancer targets, the companies said today.

Intradigm has developed a set of delivery systems for siRNA duplexes that can be delivered into pathological tissues, including human xenograft tumor models. The company said it has already used the technology to validate cancer targets.

 

Europroteome, meantime, has identified and validated its own cancer targets based on its proteomic and human-cell-based studies. The company said that using Intradigm's method to further validate these targets in tumor models "is expected to provide important information" related to its pre-clinical development program for its cancer targets.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.